Advances of transforming growth factor-β inhibitors.
- Author:
Xiao-xiong GE
;
Qi-fan ZHOU
;
Guo-liang CHEN
- Publication Type:Journal Article
- MeSH:
Epithelial-Mesenchymal Transition;
Humans;
Neoplasms;
Transforming Growth Factor beta;
antagonists & inhibitors;
Wound Healing
- From:
Acta Pharmaceutica Sinica
2015;50(4):413-418
- CountryChina
- Language:Chinese
-
Abstract:
Transforming growth factor-β is an important cytokine with various bioactivities, including embryonic development, wound healing, chemotaxis and cell cycle regulation. Epithelial-mesenchymal transition (EMT) is the main pathway of tumor cell to obtain the ability of invasion and metastasis. The TGF-β is the key factor known to induce EMT in cancer cells and plays an important role in the process. In recent years, some progress has been obtained. Some TGF-β inhibitors have approved in the market or in clinical trials. TGF-β inhibitors can play an important role on the treatment of tumors, glaucoma, liver and kidney fibrosis disease and scar repair. Novel TGF-β inhibitors reported in recent years were reviewed in this article.
